Novacyt (LSE:NCYT) Asset Impairment Charge : £0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Novacyt Asset Impairment Charge?

Novacyt's Asset Impairment Charge for the six months ended in Dec. 2023 was £0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was £0.00 Mil.

Novacyt Asset Impairment Charge Historical Data

The historical data trend for Novacyt's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novacyt Asset Impairment Charge Chart

Novacyt Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Novacyt Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Novacyt Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00 Mil.

Novacyt Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Novacyt's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Novacyt (LSE:NCYT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Novacyt SA (LSE:NCYT) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

NVYTF:USA ALNOV:France NYZ:Germany

Address

13, Avenue Morane Saulnier, Velizy-Villacoublay, FRA, 78140

Website

https://www.novacyt.com

Novacyt SA is engaged in developing and selling diagnostic products for cancer and infectious diseases. The company operates its business through the following business segments. Primerdesign is the designer, manufacturer, and marketer of molecular 'real-time' qPCR testing devices and reagents in the areas of infectious diseases based in Southampton, UK: IT-IS International segment develops PCR devices for the life sciences and food testing industry and Corporate segment.

Novacyt (LSE:NCYT) Headlines

No Headlines